Pacira BioSciences (PCRX) Capital Expenditures (2010 - 2026)

Pacira BioSciences' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 84.07% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at -$5.7 million (down 134.98% YoY), while the FY2025 annual figure was $1.5 million, down 86.2% from the prior year.
• Capital Expenditures was $1.4 million for Q1 2026 at Pacira BioSciences, up from -$13.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $13.7 million in Q4 2023 to a low of -$13.6 million in Q4 2025.
• Historically, Capital Expenditures has averaged $3.5 million across 5 years, with a median of $3.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures tumbled 264.04% in 2023, then jumped 2147.62% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $5.5 million in 2022, then jumped by 149.29% to $13.7 million in 2023, then slipped by 25.35% to $10.2 million in 2024, then plunged by 233.52% to -$13.6 million in 2025, then surged by 109.98% to $1.4 million in 2026.
• The last three Capital Expenditures figures came in at $1.4 million (Q1 2026), -$13.6 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.